Survival time outcomes in randomized, controlled trials and meta-analyses: the parallel universes of efficacy and cost-effectiveness.
about
Analysis of time to event outcomes in randomized controlled trials by generalized additive modelsMedian-based incremental cost-effectiveness ratios with censored dataDifference in Restricted Mean Survival Time for Cost-Effectiveness Analysis Using Individual Patient Data Meta-Analysis: Evidence from a Case Study.Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.Survival analysis for economic evaluations alongside clinical trials--extrapolation with patient-level data: inconsistencies, limitations, and a practical guide.Mixed response and time-to-event endpoints for multistage single-arm phase II designExtrapolation of Survival Curves from Cancer Trials Using External Information.Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma.Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment.Estimating the 95% confidence interval for survival gain between an experimental anti-cancer treatment and a control.Adjusting Survival Time Estimates to Account for Treatment Switching in Randomized Controlled Trials—an Economic Evaluation Context
P2860
Q27309297-D61AEFD6-4886-4FCC-BCCA-D1899EBADE37Q30958552-3F0800E6-9CD8-41B3-BEAD-9DC5AFF029DBQ31056094-5468CA47-FF56-4315-B27C-A398C17A1789Q31064714-C9B869E7-948B-48FB-8D0D-E71AE4D635CBQ34148380-923E1FC4-3E7E-4C8F-811E-6D0ABFADE26BQ34557762-45287DED-952A-4280-AFA3-3DAFD6388EC0Q35700578-B45C59C2-85A5-4051-9E28-74E4426BD0F7Q39342401-DEF95028-190F-461D-80F3-D2BDFA275AF3Q39767823-498E27F0-9347-450E-A9AD-11FC5E9E2BA4Q46679113-9E0221EC-6E8B-4135-A6DF-40810C9F06B1Q49164732-FE07554B-7688-4DBB-9732-36BA18B510CDQ57493510-9100D17B-9E0A-470D-B20E-6E523EE97DCD
P2860
Survival time outcomes in randomized, controlled trials and meta-analyses: the parallel universes of efficacy and cost-effectiveness.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Survival time outcomes in rand ...... ficacy and cost-effectiveness.
@en
Survival time outcomes in rand ...... ficacy and cost-effectiveness.
@nl
type
label
Survival time outcomes in rand ...... ficacy and cost-effectiveness.
@en
Survival time outcomes in rand ...... ficacy and cost-effectiveness.
@nl
prefLabel
Survival time outcomes in rand ...... ficacy and cost-effectiveness.
@en
Survival time outcomes in rand ...... ficacy and cost-effectiveness.
@nl
P2093
P1433
P1476
Survival time outcomes in rand ...... ficacy and cost-effectiveness.
@en
P2093
Mario J N M Ouwens
Patricia Guyot
P304
P356
10.1016/J.JVAL.2011.01.008
P577
2011-05-31T00:00:00Z